Read on to learn more about Wegovy, a new obesity medication. Learn how it works, whether it may be right for you and important side effects and warnings.

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?

Wegovy (semaglutide) is a weight loss medicine. The FDA first approved Wegovy in 2021 to help people who are overweight or have obesity lose weight and keep it off. In 2024, Wegovy was also ...

Wegovy is a high-dose version of Ozempic, which has been shown to decrease the risk of serious heart issues in people with diabetes. This new study is groundbreaking for focusing on people without ...

Ozempic (semaglutide) and Wegovy (semaglutide) are brand-name injections. Ozempic is approved for type 2 diabetes, but doctors may sometimes prescribe it off-label for weight loss and management.

Medicare could start covering Wegovy for certain senior citizens and other beneficiaries with a history of heart disease now that the Food and Drug Administration has approved the drugmaker Novo ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

In a head-to-head study in the New England Journal of Medicine, people taking Zepbound, Wegovy, Zepbound led to greater weight loss.

Novo Nordisk, the maker of Wegovy, announced exclusively on "Good Morning America" Tuesday that the medication will soon be available for purchase through the telehealth companies Ro, Hims and ...

Taking Wegovy (semaglutide) can be a powerful step towards achieving weight loss goals and improving overall health—especially when done in conjunction with lifestyle changes, such as following ...

Ozempic and Wegovy are made by Novo Nordisk, which is based in Denmark and has U.S. headquarters Plainsboro, New Jersey. Originally Published: January 17, 2025 at 10:45 AM CST.

The weight-loss drug Wegovy has been bombarding TV commercial breaks with ads, more than a year after its manufacturer, Novo Nordisk, limited starter-dose supplies in the U.S. to get a handle on ...